Scientific Presentations
Abstracts from our breaking clinical trials
2021 ASH Annual Meeting
At ASH this year, we will share new data from our robust portfolio and pipeline of advanced therapeutic platforms in cancer and blood disorders, showcasing the impact of our bold science in research.
Bold Science: Transforming Lives, Striving for Cures
Reimagining Cancer and Blood Disorders
Novartis continues to pursue scientific breakthroughs with the ambition to transform lives and renew patients’ hopes for the future. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines.
Pipeline
View our broad research portfolio with innovative compounds in all phases of development.
Focus Areas
Focus Areas
Malignant Hematology
Malignant Hematology
Non-Malignant Hematology
Non-Malignant Hematology
Our 4 Bold Approaches to Cancer Treatment
Our 4 Bold Approaches to Cancer Treatment
Reimagining Cancer & Blood Disorders
Novartis is uniquely positioned to lead the next wave of novel investigational treatments through our strengths in 4 therapeutic platforms: targeted therapy, radioligand therapy, cell & gene therapy, and immunotherapy.
